SAN JOSE, Calif., July 23, 2018 /PRNewswire/ -- Integrated Device Technology, Inc. (IDT) (NASDAQ: IDTI), announced that its customer Senseonics (Germantown, MD) received FDA approval for its Eversense® Continuous Glucose Monitoring (CGM) System for people with diabetes. The Eversense System consists of an implantable, fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app. The system is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months. The Eversense System addresses many of the barriers to CGM use. It displays glucose values, trends and alerts. The sensor, which is inserted subcutaneously in the upper arm by a physician via a brief in-office procedure, lasts up to three months, thereby eliminating the need for patients to self-administer the weekly or biweekly sensor insertions required by traditional CGM systems.
An IDT® ASIC (Application Specific Integrated Circuit) is the "heart" of the implantable sensor platform that measures blood glucose levels in people with diabetes. The sensor IC from IDT allows, through on-chip integrated photodiodes and LEDs mounted on the IC, high-precision wireless fluorimetry measurements. These measurement results will get adapted through a programmable trans-impedance amplifier and digitized by an ADC. The resulting data will be transmitted via an integrated ISO-compliant Near Field Communication (NFC) interface to an external transmitter. The power for the IC, and thus for the sensor, is harvested through the same NFC. The necessary electrical field is generated by the external transmitter, which is also used for the bidirectional communication. So once implanted, the sensor requires no penetration of the skin to operate and thus enables a long-term continuous glucose sensor lasting for up to three months in people.
Andrew DeHennis, Senseonics' director of Electrical Engineering, said "We're very pleased to receive FDA approval that allows us to make Eversense available in the United States, as it is already in many European markets. One of the key parts of the Eversense System, which enabled this success, is IDT's leading-edge sensor ASIC. Without their engineering excellence, this important step for Senseonics would have not been achievable."
"We congratulate Senseonics on their major accomplishment in receiving FDA approval for their Eversense System. IDT's advanced ASIC technology is a great example of how miniaturization can improve medical care, and our leading-edge ASIC provides the highest level of analog-digital mixed signal system integration. We are excited to be part of this important industry solution, which will improve how diabetes patients manage their health and provide a higher quality of life for patients" said Uwe Günther, general manager of IDT's Industrial Unit, a part of the company's Automotive and Industrial Group.
Integrated Device Technology, Inc. develops system-level solutions that optimize its customers' applications. IDT's market-leading products in RF, high performance timing, memory interface, real-time interconnect, optical interconnect, wireless power, and smart sensors are among the company's broad array of complete mixed-signal solutions for the communications, computing, consumer, automotive and industrial segments. Headquartered in San Jose, Calif., IDT has design, manufacturing, sales facilities and distribution partners throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market® under the symbol "IDTI." Additional information about IDT can be found at idt.com. Follow IDT on Facebook, LinkedIn, Twitter, and YouTube.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.
© 2018, Integrated Device Technology, Inc. IDT and the IDT logo are trademarks or registered trademarks of Integrated Device Technology, Inc., and its worldwide subsidiaries. Eversense is a trademark or registered trademark of Senseonics, Inc. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
Director, Demand Creation & Communications
Phone: (408) 574-6640
View original content with multimedia:http://www.prnewswire.com/news-releases/idts-customer-senseonics-receives-fda-approval-for-its-implantable-glucose-sensor-300684424.html
SOURCE Integrated Device Technology, Inc.